Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients Source: Eur Respir J 2014; 44: 527-529 Year: 2014
The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Treatment of COPD Year: 2009
Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2 -agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Source: Eur Respir J 2011; 37: 273 Year: 2011
Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Once-daily NVA237 improves lung function in COPD patients: Pooled results of the GLOW1 and GLOW2 studies Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009